Print This Article (X)  | Close this Window (X)
Media Contact: Vincent Joseph Dollard
  (404) 727-3366
31 May 2007
Emory's Fadlo R. Khuri Elected to American Society of Clinical Investigation
Fadlo R. Khuri, MD, deputy director for Clinical and Translational Research at Emory University's Winship Cancer Institute, has been elected to the prestigious American Society of Clinical Investigation.

ASCI, established in 1908, is one of the nation's oldest and most respected medical honor societies. Dr. Khuri is the first physician scientist from Emory's Hematology and Oncology section to be elected to ASCI.

Each year, ASCI members nominate those whom they feel have made significant accomplishments in their careers at a relatively early age - 45 or younger. Candidates for membership must be nominated and seconded by ASCI members.

"I am truly honored to have been nominated and elected into ASCI," says Dr. Khuri. "As we move forward in cancer research and treatment, the ability to collaborate and share ideas is critical to our success. Organizations such as ASCI play an important role in bringing physicians and researchers together for this purpose."

In addition to serving as deputy director at Winship, Dr. Khuri serves as the Blomeyer Professor of Hematology and Oncology; professor of Hematology & Oncology, Otolaryngology, Medicine and Pharmacology; and chief medical officer and co-director of the Institute's Cancer Drug Discovery, Development, and Delivery Program.

In 2006, Dr. Khuri's translational research was acknowledged through award of a National Cancer Institute Program Project Grant of $7.9 million for his project, "Targeting Cell Signaling in Lung Cancer to Enhance Therapeutic Efficacy."

Thomas Lawley, MD, dean of Emory University School of Medicine and an ASCI member, notes the importance of Dr. Khuri's work and his election into ASCI.

"Membership is considered an exceptional honor in academic medicine and industry, and Dr. Khuri has certainly earned this honor," says Dr. Lawley. "He is devoted to improving therapies for tobacco-related cancers, which account for the majority of cancer deaths, and his focus is on developing novel treatment strategies for patients facing poor outcomes. Dr. Khuri's work is advancing the body of knowledge in cancer research and treatment."

Dr. Khuri is the recipient of numerous awards, including being listed among America's Top Doctors and the Marquis Who's Who in the World. He is a Georgia Cancer Coalition Distinguished Clinical Scholar and serves on the editorial boards of 7 journals, including the Journal of Clinical Oncology, Clinical Cancer Research and Cancer, and has published over 100 peer reviewed articles in elite journals including Nature Medicine, Journal of the National Cancer Institute, Cancer Research and the Journal of Clinical Oncology.

Dr. Khuri earned his bachelor's degree from Yale University and his medical degree from Columbia University College of Physicians and Surgeons. He completed his residency in Internal Medicine at the Boston City Hospital, Boston University School of Medicine. He then completed a fellowship in Hematology and Medical Oncology at the New England Medical Center, Tufts University School of Medicine. He is certified by the American Board of Internal Medicine in Internal Medicine and Medical Oncology and is an active member of the American Association for Cancer Research, and the American Society of Clinical Oncology. He was on faculty at the University of Texas M.D. Anderson Cancer Center from 1995-2002 before joining Emory University.

© Emory University 2022

<<::Back to Press Releases